TTP company Cellular Origins has completed a $40 million Series A financing round to accelerate its development of scalable cell therapy manufacture. The Series A financing was led by Johnson & Johnson, through its corporate venture capital organisation, Johnson & Johnson Innovation, with the syndicate comprising Highland Europe, BGF,… Read More
Cellular Origins, the Cell and Gene Therapy Catapult (CGT Catapult), and Resolution Therapeutics have formed a consortium to deliver a fully automated, scalable cell therapy manufacturing platform. The consortium has been awarded a cross-industry Smart Grant of £1 million from Innovate UK, the UK’s national innovation agency. Read More
Cellular Origins, a company focused on enabling scalable, cost-effective and space-efficient manufacture of cell and gene therapies (CGTs), has launched Constellation, its closed, configurable, robotic platform at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting 2023. Designed to automate the manufacturing of advanced therapies… Read More
